MDNews

Detecting Heart Attacks Before They Happen




The AngelMed Guardian System is an implantable device designed to notify patients when a heart attack may be imminent.

Is Your Patient a Candidate?

To find out if your patient could be a potential candidate for the ALERTS trial, please have him or her complete a survey on the AngelMed website.

Unlike a pacemaker, the Guardian System monitors the heart's electrical signal 24 hours a day, seven days a week for ischemic events at normal, low or irregular heartbeats. The device looks for changes that may indicate an oncoming heart attack and has the potential to detect heart attacks that have atypical symptoms or no symptoms at all.

If the system senses a potential heart attack, the monitor alerts the wearer through beeping and flashing that he or she should immediately contact 911 or his or her health care provider. At the hospital, a physician can retrieve information collected by the Guardian System on a computer.

Last year, Angel Medical Systems announced that it had received Conformité Européenne (CE) Mark approval for the commercial sale of The AngelMed Guardian System in Europe. A CE mark means that the system is in compliance with all EU regulations.

To achieve approval in the United States, Angel Medical Systems is conducting the ALERTS trial to test the effectiveness of the Guardian System at reducing the time to treatment, decreasing damage to the heart muscle and improving survival rates.

“Over the past two decades, it has routinely taken patients 2-3 hours to arrive at the hospital with a heart attack,” said Dr. C. Michael Gibson of Harvard Medical School, leader of the ALERTS study, in a press release. “Our initial studies indicate that this device may reduce that time to approximately 20 minutes. When time is muscle, every minute counts and our hope is that survival will be improved.”

To find out more about the ALERTS clinical trial, visit ClinicalTrials.gov.


COMMENT ON THIS ARTICLE